We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Winlevi

News List

Sun Pharma and Cassiopea SpA sign license and supply agreements for Winlevi expresspharma
July 27, 2021
Sun Pharmaceuticals and Cassiopea SpA have signed licence and supply agreements for Winlevi (clascoterone cream 1%) in the United States (US) and Canada.
AMRI Named Exclusive API Supplier for Recently Approved Acne Treatment contractpharma
November 09, 2020
Albany Molecular Research, Inc. (AMRI) has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s recently approved acne treatment, Winlevi (clascoterone) cream 1%.
US FDA approves Winlevi, topical acne treatment from Cassiopea expresspharma
August 31, 2020
Reportedly, the last FDA approval of an acne drug with a new mechanism of action (MOA) occurred nearly 40 years ago.
Cassiopea secures FDA approval for Winlevi topical acne treatment pharmaceutical-technology
August 28, 2020
Italian speciality pharmaceutical firm Cassiopea has received approval from the US Food and Drug Administration (FDA) for Winlevi (clascoterone cream 1%) as a topical treatment for acne vulgaris.